Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β1-mediated endothelial–mesenchymal transition
Acta Pharmaceutica Sinica B · 2026-09 · 16 (9) · 5901-5925
DOI: 10.1016/j.apsb.2026.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-09. Verfasst von Yixiu Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, College of Pharmacy, Harbin Medical University, Ha…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Heilongjiang Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis is driven by metabolic dysregulation and endothelial dysfunction; however, the precise molecular mechanisms underlying its pathogenesis remain incompletely elucidated. Fibrinogen-like protein 1 (FGL1) is a well-established hepatokine with critical roles in regulating tumorigenesis and metabolic dysfunction, while its involvement in atherogenesis remains unclear. Our clinical and preclinical studies revealed elevated plasma FGL1 levels in atherosclerotic patients and mice, correlating with arterial stenosis severity. Prolonged high-fat diet exposure specifically upregulated hepatic FGL1 expression. Hepatic FGL1 overexpression accelerated atherosclerosis, while liver-specific knockdown reduced plaque burden. Exogenous administration of FGL1 accelerated endothelial injury and atherosclerosis progression. Mechanistically, liver-derived FGL1 accumulates in vascular endothelium through fibrinogen C-terminal domain Trp225-mediated binding to integrin β1's vWFA domain. This interaction promotes the conformational change of integrin β1 and the formation of integrin β1/ILK1 complex, co-activating FAK/ERK and Smad signaling to drive transcriptional reprogramming of endothelial cells. Therapeutic interventions targeting FGL1-integrin β1 axis by integrin β1 blocking antibody, FGL1-neutralizing antibody, or RGD peptide effectively attenuated endothelial injury and atherogenic progression in murine models. These findings establish hepatic FGL1 as a novel endocrine regulator of vascular pathophysiology, highlighting the FGL1-integrin β1 axis as a promising therapeutic target for endothelial protection and atherosclerosis management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
- Key Laboratory of Cardiovascular Medicine Research of Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
- Heilongjiang Medical Academy, Harbin Medical University, Harbin 150081, China.
- Department of Cardiology at the Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
Förderung
- Heilongjiang Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhao, Y., Chen, H., Yin, L., Meng, R., Zheng, J., Zhang, Y., Wang, Z., Chen, Y., Xu, R., Liu, J., Li, Y., An, N., Li, H., & Zhang, Y. (2026). Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β1-mediated endothelial–mesenchymal transition. Acta Pharmaceutica Sinica B, 16(9), 5901-5925. https://doi.org/10.1016/j.apsb.2026.06.005
Vancouver
Zhao Y, Chen H, Yin L, Meng R, Zheng J, Zhang Y, et al. Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β1-mediated endothelial–mesenchymal transition. Acta Pharmaceutica Sinica B. 2026;16(9):5901-5925. doi:10.1016/j.apsb.2026.06.005
BibTeX
@article{Zhao2026,
author = {Zhao, Yixiu and Chen, Huan and Yin, Liuqing and Meng, Ruirui and Zheng, Jiangfei and Zhang, Yue and Wang, Zhiqi and Chen, Yi and Xu, Rui and Liu, Jing and Li, Yanxi and An, Na and Li, Houwei and Zhang, Yan},
title = {Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β1-mediated endothelial–mesenchymal transition},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {9},
pages = {5901--5925},
doi = {10.1016/j.apsb.2026.06.005}
}
EUVIMED